Evidence map›Paper›PMID 37439512›Full record

ArticleCurrent protocols2023

Theoretical Considerations for Optimizing the Use of Optogenetics with Complex Behavior.

Bess Glickman, Ryan T LaLumiere

Open access · hybridAbstract read
In one paragraph

Article in Current protocols, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Bess GlickmanInterdisciplinary Graduate Program in Neuroscience, University of Iowa, Iowa City, Iowa.
Ryan T LaLumiereInterdisciplinary Graduate Program in Neuroscience, University of Iowa, Iowa City, Iowa.
University of Iowa · US

Funding

Neural circuits and mechanisms underlying active and passive stress copingR01MH132207 · NIMH · UNIVERSITY OF IOWA · PI RYAN T LALUMIERE, JASON J RADLEY · 2023 to 2026
$2.6M
Neural systems controlling the inhibition of heroin seeking R01DA048055 · NIDA · UNIVERSITY OF IOWA · PI LALUMIERE, RYAN T · 2019 to 2023
$2.3M
Neural systems mediating the extinction and inhibition of cocaine seekingR01DA049139 · NIDA · UNIVERSITY OF IOWA · PI LALUMIERE, RYAN T · 2020 to 2024
$2.2M
NIDA NIH HHS R01 DA048055NIDA NIH HHS R01 DA049139NIH HHS DA048055NIH HHS DA049139NIH HHS MH132207NIMH NIH HHS R01 MH132207
6 · The paper itself

Abstract

Optogenetic approaches have allowed researchers to address complex questions about behavior that were previously unanswerable. However, as optogenetic procedures involve a large parameter space across multiple dimensions, it is crucial to consider such parameters in conjunction with the behaviors under study. Here, we discuss strategies to optimize optogenetic approaches with complex behavior by identifying critical experimental design considerations, including frequency specificity, temporal precision, activity-controlled optogenetics, stimulation pattern, and cell-type specificity. We highlight potential limitations or theoretical considerations to be made when manipulating each of these factors of optogenetic experiments. This overview emphasizes the importance of optimizing optogenetic study design to enhance the conclusions that can be drawn about the neuroscience of behavior. © 2023 The Authors. Current Protocols published by Wiley Periodicals LLC.

Indexed as

NeurosciencesOptogeneticsHumansResearch DesignResearch Personnelactivity-controlled optogeneticscell-type specificityfrequency specificitystimulation patterntemporal precision

Identifiers

PMID37439512
PMCPMC10406170
OpenAlexW4384126455

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.